Cargando…

Poor prognosis of pulmonary sarcomatoid carcinoma with KRAS mutation and ALK fusion

Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of poorly differentiated non-small-cell lung cancer (NSCLC), and no effective treatment is available in clinical practice currently. In the present report, a 61-year-old male patient was hospitalized due to cough, dyspnea, and right chest pain....

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Fangmin, Gu, Qihua, Hu, Chengping, Cai, Xiaoling, Lei, Shuhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6501700/ https://www.ncbi.nlm.nih.gov/pubmed/31118683 http://dx.doi.org/10.2147/OTT.S196751

Ejemplares similares

Synchronal pulmonary sarcomatoid carcinoma and lung adenocarcinoma EML4-ALK fusion: A case report
por: Wang, Mingting, et al.
Publicado: (2022)

Pulmonary Sarcomatoid Carcinoma with ALK Rearrangement: Frequency, Clinical-Pathologic Characteristics, and Response to ALK Inhibitor()
por: Chen, Xinru, et al.
Publicado: (2017)

Sarcomatoid carcinoma of colon: extremely poor prognosis
por: Choi, Yoon Young, et al.
Publicado: (2011)

Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression
por: Zhang, Xuchao, et al.
Publicado: (2010)

ALK1 Gene Rearranged Pulmonary Sarcomatoid Carcinoma Masquerading as Tuberculosis in a Young Male
por: Sahay, Ayushi, et al.
Publicado: (2021)

Overexpression of p53R2 is associated with poor prognosis in lung sarcomatoid carcinoma
por: Chen, Jiewei, et al.
Publicado: (2017)

The Intrapleural Bridge Connection is One of the Reasons for Unknown Localized Pleural Adhesion
por: Gu, Qihua, et al.
Publicado: (2021)

The Prognosis of Pulmonary Sarcomatoid Carcinoma: Development and Validation of a Nomogram Based on SEER
por: Xie, Yuanyuan, et al.
Publicado: (2022)

Immunophenotyping of pulmonary sarcomatoid carcinoma
por: Ma, Yu, et al.
Publicado: (2022)

PIK3CA Mutations Frequently Coexist with EGFR/KRAS Mutations in Non-Small Cell Lung Cancer and Suggest Poor Prognosis in EGFR/KRAS Wildtype Subgroup
por: Wang, Lei, et al.
Publicado: (2014)

Ductal activation of oncogenic KRAS alone induces sarcomatoid phenotype
por: Fu, Yong, et al.
Publicado: (2015)

ALK gene amplification is associated with poor prognosis in colorectal carcinoma
por: Bavi, P, et al.
Publicado: (2013)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis
por: Lohinai, Zoltan, et al.
Publicado: (2017)

Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokers
por: Ahn, Jin Woo, et al.
Publicado: (2014)

Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia
por: Brcic, Luka, et al.
Publicado: (2016)

An immune-based risk-stratification system for predicting prognosis in pulmonary sarcomatoid carcinoma (PSC)
por: Guo, Haoyue, et al.
Publicado: (2021)

Dual drive coexistence of ALK rearrangement and KRAS mutation advanced lung adenocarcinoma and response to crizotinib
por: Zhu, You-Cai, et al.
Publicado: (2019)

Pulmonary sarcomatoid carcinoma presenting both ALK rearrangement and PD-L1 high positivity: A case report on the therapeutic regimen
por: D’Antonio, Federica, et al.
Publicado: (2019)

Metastatic EML4-ALK fusion detected by circulating DNA genotyping in an EGFR-mutated NSCLC patient and successful management by adding ALK inhibitors: a case report
por: Liang, Wenhua, et al.
Publicado: (2016)

Genetic testing and prognosis of sarcomatoid hepatocellular carcinoma patients
por: Jia, Bin, et al.
Publicado: (2023)

Pulmonary sarcomatoid carcinoma: a case report
por: Shen, Xiao-yong, et al.
Publicado: (2013)

Definitive Chemoradiotherapy for Advanced Pulmonary Sarcomatoid Carcinoma
por: Takeda, Kazuya, et al.
Publicado: (2016)

Pulmonary sarcomatoid carcinoma: University of Cincinnati experience
por: Karim, Nagla Abdel, et al.
Publicado: (2017)

Clinical and molecular characteristics of pulmonary sarcomatoid carcinoma
por: Sim, Jae Kyeom, et al.
Publicado: (2018)

Pulmonary sarcomatoid carcinoma: progress, treatment and expectations
por: Li, Xin, et al.
Publicado: (2020)

Approaches to Tumor Classification in Pulmonary Sarcomatoid Carcinoma
por: Baldovini, Chiara, et al.
Publicado: (2019)

MET alterations in advanced pulmonary sarcomatoid carcinoma
por: Gong, Chen, et al.
Publicado: (2022)

Sarcomatoid intrahepatic cholangiocarcinoma in a patient with poor prognosis: a case report and literature review
por: Li, Xu, et al.
Publicado: (2020)

High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis
por: Thomas, Anish, et al.
Publicado: (2015)

Long-term outcomes and prognosis for patients with sarcomatoid hepatocellular carcinoma
por: Zhou, Cheng, et al.
Publicado: (2022)

Clinical characteristics and prognostic factors of pulmonary sarcomatoid carcinoma
por: Zhao, Chenguang, et al.
Publicado: (2022)

Emerging new evidence for the treatment of pulmonary sarcomatoid carcinoma
por: Akaba, Tomohiro, et al.
Publicado: (2023)

Clinical outcomes of radical radiotherapy for pulmonary sarcomatoid carcinoma
por: Lee, Choong-won, et al.
Publicado: (2023)

Preoperative CT findings and prognosis of pulmonary sarcomatoid carcinoma: comparison with conventional NSCLC of similar tumor size
por: Tang, Wenjian, et al.
Publicado: (2023)

Coexistence of two missense mutations in the KRAS gene in adenocarcinoma of the lung: a possible indicator of poor prognosis
por: Spinelli, Manuela, et al.
Publicado: (2022)

Genetic alterations of KRAS and TP53 in intrahepatic cholangiocarcinoma associated with poor prognosis
por: Peng, Jianbo, et al.
Publicado: (2023)

Poor Prognosis of Pulmonary Adenosquamous Carcinoma with NRAS and HRAS Double Mutation
por: Zhao, Jidong, et al.
Publicado: (2021)

Metastatic pulmonary carcinoids with EML4-ALK fusion response to ALK inhibitors: two case reports and review of literature
por: Lei, Xi, et al.
Publicado: (2022)

The poor prognosis of sarcomatoid carcinoma arising from low grade serous ovarian cancer: A case report and review of the literature
por: Haight, Paulina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i9uejgkbaf8vc6gm4vc8ftp9cj